Cantor Fitzgerald Upgrades Kura Oncology (NASDAQ:KURA) to Strong-Buy

Kura Oncology (NASDAQ:KURA) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

Other research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. JMP Securities restated a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Jefferies Financial Group dropped their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Finally, Bank of America reduced their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Stock Up 1.1 %

Shares of NASDAQ:KURA opened at $7.33 on Tuesday. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $8.10 and its 200-day simple moving average is $13.64. The company has a market cap of $570.01 million, a price-to-earnings ratio of -3.11 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, equities research analysts predict that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock worth $92,307 in the last quarter. 5.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Harbor Capital Advisors Inc. raised its holdings in shares of Kura Oncology by 21.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock valued at $924,000 after buying an additional 8,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Kura Oncology by 35.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after purchasing an additional 7,722 shares during the period. Intech Investment Management LLC acquired a new position in shares of Kura Oncology during the third quarter worth $298,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Kura Oncology by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock valued at $12,212,000 after purchasing an additional 14,106 shares during the period. Finally, Algert Global LLC grew its holdings in Kura Oncology by 4.4% during the 3rd quarter. Algert Global LLC now owns 272,276 shares of the company’s stock valued at $5,320,000 after purchasing an additional 11,493 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.